Download from app store
We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Published in Oncology

Journal Scan / Research · October 19, 2022

Osimertinib as a First-Line Treatment for Elderly Patients With EGFR Mutation–Positive Advanced NSCLC

The Oncologist


Additional Info

Disclosure statements are available on the authors' profiles:

The Oncologist
A Phase II Trial on Osimertinib as a First-Line Treatment for EGFR Mutation-Positive Advanced NSCLC in Elderly Patients: The SPIRAL-0 Study
Oncologist 2022 Oct 01;[EPub Ahead of Print], Y Chihara, T Takeda, Y Goto, Y Nakamura, Y Tsuchiya-Kawano, A Nakao, K Onoi, M Hibino, M Fukuda, R Honda, T Yamada, R Taniguchi, S Sakamoto, K Date, S Nagashima, S Tanzawa, K Minato, K Nakatani, M Izumi, T Shimose, J Kishimoto, J Uchino, K Takayama

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading